Showing results (1151-1160 of 8,959) with videos related to
Sort By:
Pageof 896
Journal of Hepatology|February 4, 2014
Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinomaJonggi Choi, Ju Hyun Shim, Yong Moon Shin, et al.Journal of Hepatology|February 4, 2014
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patientsStefan Zeuzem, Ralph DeMasi, Alessandra Baldini, et al.Journal of Hepatology|February 1, 2025
Moving diagnosis of liver fibrosis into the communityElisa Pose, Salvatore Piano, Maja Thiele, et al.Journal of Hepatology|February 6, 2025
Freiburg index of post-TIPS survival (FIPS) identifies patients at risk of further decompensation and ACLF after TIPSLukas Sturm, Michael Schultheiss, Fabian Stöhr, et al.Journal of Hepatology|January 25, 2025
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver diseaseTerry Cheuk-Fung Yip, Hye Won Lee, Huapeng Lin, et al.Journal of Hepatology|January 12, 2025
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trialJasmohan S Bajaj, Andrew Fagan, Edith A Gavis, et al.Journal of Hepatology|January 9, 2025
Spliced exon9 ADRM1 promotes liver oncogenicity via selective degradation of tumor suppressor FBXW7Yanmei Sun, Mingjing Xu, Ho Lee Wan, et al.Journal of Hepatology|December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaSarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.Journal of Hepatology|November 28, 2024
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver diseaseJuan Pablo Arab, Luis Antonio Díaz, Jürgen Rehm, et al.Journal of Hepatology|December 21, 2024
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled studyLin Xiang, Guixia Wang, Yulei Zhuang, et al.Pageof 896